4 research outputs found
Articles Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial
Get PDFSummary Background Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in combination with other antiemetic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy in adults, but its effi cacy and safety in paediatric patients are unknown. We did this phase 3 trial to examine the safety and effi cacy of such treatment in children
Randomized, placebo-controlled, phase III study of aprepitant in preventing chemotherapy-induced nausea and vomiting in children: Analysis by age group.
No full text
